



SUVEN  
LIFE SCIENCES LIMITED

MAKING  
PROGRESS

**SUVEN**  
**LIFE SCIENCES LIMITED**  
BUSINESS RESPONSIBILITY REPORT  
[Under Regulation 34(2)(f)]  
**2020-21**



# ABOUT THIS REPORT

The reporting framework used in this report is based on the 'National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business (NVGs)' released by the Ministry of Corporate Affairs, Government of India, in July 2011, which contains 9 Principles and Core Elements for each of the Nine Principles.

This is Suven's fourth Business Responsibility Report. This report is intended to transparently disclose our performance based on the principles provided in the NVGs and is meant for all our stakeholders. We welcome your thoughts, comments and feedback as this will allow us to improve on our reporting and disclosure standards.

If you would like to send us feedback about this report, please email to [investorservices@suven.com](mailto:investorservices@suven.com).

## DISCLOSURES ON THE NINE PRINCIPLES AS CHARTED BY THE MINISTRY OF CORPORATE AFFAIRS IN THE "NATIONAL VOLUNTARY GUIDELINES (NVG) ON SOCIAL, ENVIRONMENTAL AND ECONOMIC RESPONSIBILITIES OF BUSINESS".

### PRINCIPLE 1

#### **Ethics Transparency & Accountability**

Businesses should conduct and govern themselves with Ethics, Transparency and Accountability.

### PRINCIPLE 2

#### **Product Life Cycle Sustainability**

Businesses should provide goods and services that are safe and contribute to sustainability throughout their lifecycle.

### PRINCIPLE 3

#### **Employee Well-Being**

Businesses should promote the well-being of all employees.

### PRINCIPLE 4

#### **Stakeholder Engagement**

Businesses should respect the interests of and be responsive towards all stakeholders, especially those who are disadvantaged, vulnerable and marginalised.

### PRINCIPLE 5

#### **Human Rights**

Businesses should respect and promote human rights.

### PRINCIPLE 6

#### **Environment**

Businesses should respect, protect and make efforts to restore the environment.

### PRINCIPLE 7

#### **Policy Advocacy**

Businesses, when engaged in influencing public regulatory policy, should do so in a responsible manner.

### PRINCIPLE 8

#### **Inclusive Growth and Equitable Development**

Businesses should support inclusive growth and equitable development.

### PRINCIPLE 9

#### **Customer Value**

Businesses should engage with and provide value to their customers and consumers in a responsible manner.



Our resources

**"I TAKE IMMENSE PRIDE IN STATING THAT THE SUVEN LIFE SCIENCES TEAM COMPRISES OF MAVERICKS WHO DARE TO LOOK AT THE WORLD DIFFERENTLY; WE ARE SINGULARLY FOCUSED ON**

**DEVELOPING A LIFE-CHANGING REMEDY THAT COULD BENEFIT MILLIONS ACROSS THE WORLD."**



**Venkateswarlu Jasti**  
Chairman & CEO

*Dear Shareholders,*

I hope you are safe and healthy. For the carefree world as we knew it, has completely changed with the sudden spread of the pandemic across the globe.

While I am saddened by the colossal loss to mankind by this microscopic enemy, I am pleased with the progress made by the research fraternity across the world who came together in this time of crisis to develop relevant solutions for this ailment and effective vaccines that minimise the impact on humans from this contagion. This is very heartening progress for it builds confidence to survive and succeed.

From a dispassionate perspective, this pandemic has proved that progress, in this highly competent world, is the key to survival. It is clear that a lack of progress will result in the gradual decline of success. It must also be noted that progress is not a one-time act, it is a repetitive process and must always be the foremost goal of any society for it to achieve the greatest peaks.

This is the belief we nurture at Suven Life Sciences. Every day we strive to progress – in our successes and learnings (we have no failures).

In FY21, we achieved considerable progress in our research endeavours which fills our hearts and minds with considerable satisfaction.

Our lead molecule Masupirdine, is readying for its Phase 2/3 Clinical Trial.

Although patient enrolment for the Clinical Trial of our second lead molecule Samelisant (SUVN-G3031) faced headwinds, we had some positives for this molecule. The Data Safety Monitoring Board (DSMB) confirmed that the molecule does not have any side effect. An important positive for us. Further, they suggested that we increase the patient pool for adding one more indication. While this will delay the end result by about 18 months, but some journeys are definitely worth the wait.

Internally, we will continue to progress our existing assets further along the development path. Our two molecules are ready at the Phase 2 Proof of Concept stage. We hope to initiate Clinical Trials for them shortly.

We invested US\$6.18 mn in clinical trials in FY21. We plan to pump in another US\$10 mn in FY22.

Many have asked what drives us to burn our such sizeable funds, with no assured revenue visibility. Our perspective is that this is not a burn but the need of the hour. Because brain-related disorders are quietly but steadily become increasingly intense. And before we know it will consume people, families and nations, if we do not push ourselves to develop relevant solutions now.

I take immense pride in stating that the Suven Life Sciences team comprises of mavericks who dare to look at the world differently; we are singularly focused on developing a life-changing remedy that could

benefit millions across the world.

We are charged with the recent FDA approval for Aduhelm (aducanumab), a molecule of a global pharma company, to treat patients with Alzheimer's disease. It is the first novel therapy approved for Alzheimer's since 2003. It showcases progress. It provides hope. It gives a direction.

On funding our future journey, we have enough funds to carry our research for 12 months. Further, I have committed ₹147 crore to Suven Life Sciences from my own resources. This should be sufficient to carry on for another 12-18 months. Hopefully by then our molecules would have made good progress to generate sufficient global interest.

Over the long-term, Suven Life Sciences will continue to remain squarely focused on its sustainability goals. This strategic direction will enable it to nurture lasting relations with all its stakeholders.

Warm regards

**Venkateswarlu Jasti**  
Chairman & CEO



SECTION A

# GENERAL INFORMATION ABOUT THE COMPANY

1.	Corporate Identity Number (CIN) of the Company	L24110TG1989PLC009713
2.	Name of the Company	SUVEN LIFE SCIENCES LIMITED
3.	Registered address	8-2-334 I SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034, Telangana, India
4.	Website	www.suven.com
5.	E-mail id	investorservices@suven.com
6.	Financial Year reported	April 2020 to March 2021
7.	Sector(s) that the Company is engaged in (industrial activity code-wise)	Pharmaceuticals
8.	List three key products/ services that the Company manufactures/ provides (as in balance sheet)	The Company is a research-focused organisation. As such, it does not have any product for marketing. The Company provide research services to global pharma/ life sciences entities.
9.	Total number of locations where business activity is undertaken by the Company	Two R&D facilities at Jeedimetla and Pashamylaram in Telangana.
(a).	Number of International Locations (Provide details of major 5)	One Clinical Development Centre through our wholly-owned subsidiary in New Jersey.
(b).	Number of National Locations	Two R&D centers
10.	Markets served by the Company - Local/ State/ National/ International	Refer to segment report, page 121

SECTION B

# FINANCIAL DETAILS OF THE COMPANY



1.	Paid up Capital (INR)	₹1,272.82 lakhs
2.	Revenue (INR) (standalone)	₹1,348 lakhs (as on 31st March, 2021)
3.	Net Profit/(Loss) for the year (INR) (standalone)	₹(2,263) lakhs (as on 31st March, 2021)
4.	Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax (%)	Nil
5.	List of activities in which expenditure in 4 above has been incurred:-	NA

SECTION C

# OTHER DETAILS

1.	Does the Company have any Subsidiary Company/ Companies?	Yes
2.	Do the Subsidiary Company/ Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s)	No
3.	Do any other entity/ entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/ entities? [Less than 30%, 30-60%, More than 60%]	No



SECTION D

# BR INFORMATION

1. Details of Director/Directors responsible for BR

**(a) Details of the Director/Director responsible for implementation of the BR policy/policies**

1.	DIN Number	00278028
2.	Name	Venkateswarlu Jasti
3.	Designation	Chairman & CEO

**(b) Details of the BR head**

No.	Particulars	Details
1.	DIN Number (if applicable)	00278028
2.	Name	Venkateswarlu Jasti
3.	Telephone number	040-23541142
4.	e-mail id	info@suvan.com


2. Principle-wise (as per NVGs) BR Policy/policies

**(a) Details of compliance (Reply in Y/N)**

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8
1.	Do you have a policy/ policies for...	Yes							
2.	Has the policy being formulated in consultation with the relevant stakeholders?	Yes							
3.	Does the policy conform to any national/ international standards? If yes, specify? (50 words)	Yes							
4.	Has the policy being approved by the Board? Is yes, has it been signed by MD/ owner/ CEO/ appropriate Board Director?	Yes							
5.	Does the Company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	Yes							
6.	Indicate the link for the policy to be viewed online?	#	#	#	#	#	#	#	#
7.	Has the policy been formally communicated to all relevant internal and external stakeholders?	Yes							
8.	Does the Company have a grievance redressal mechanism related to the policy/ policies to address stakeholders' grievances related to the policy/ policies?	Yes							
9.	Has the Company carried out independent audit/ evaluation of the working of this policy by an internal or external agency?	Yes							

**# Details of information and links provided below.**

P1: Refer to Whistle Blower Policy and Code of Conduct and Ethics P2: Available on our intranet P3: Available on our intranet P4: Refer to the CSR Policy (available on www.suvan.com) and Sustainability Policy available on intranet P5: Available on our intranet P6: Available on our intranet P7: Available on our intranet P8: Refer to the CSR committee charter, CSR Policy (available on www.suvan.com) and Sustainability Policy available on intranet P9: Available on our intranet.



SECTION E

# PRINCIPLE-WISE PERFORMANCE

(b) If answer to the question at serial number 1 against any principle, is 'No', please explain why: (Tick up to 2 options)

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8
1.	The company has not understood the Principles								
2.	The company is not at a stage where it finds itself in a position to formulate and implement the policies on specified principles	Not applicable							
3.	The company does not have financial or manpower resources available for the task								
4.	It is planned to be done within next 6 months								
5.	It is planned to be done within the next 1 year								
6.	Any other reason (please specify)								

### 3. Governance related to BR

1.	Indicate the frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR performance of the Company. Within 3 months, 3-6 months, Annually, More than 1 year	We have constituted a Corporate Social Responsibility (CSR) committee of the Board which oversees our CSR activities. The Committee meets once in year to assess the BR performance and align strategies in line with external realities.
2.	Does the Company publish a BR or a Sustainability Report? What is the hyperlink for viewing this report? How frequently it is published?	The Company publishes a BR and a Sustainability Report annually. Our Sustainability Report can be viewed at <a href="http://www.suven.com/annual-reports.html">http:// www.suven.com/annual-reports.html</a>

#### Principle 1

**1. Does the policy relating to ethics, bribery and corruption cover only the Company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/ Contractors/ NGOs /Others?**

Our policies on ethics, bribery and corruption cover the Company, its subsidiaries and branches and our suppliers and contractors.

**2. How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about 50 words or so.**

Suven's stakeholders include investors, employees, customers, suppliers, contractors, bankers and financial institutions, government agencies and the local community. For details of Shareholders complaints, please refer to the Investors section in our Annual Report 2021.

#### Principle 2

**1. List up to 3 of your products or services whose design has incorporated social or environmental concerns, risks and/ or opportunities.**

(a). Being research and development company, Suven Life Sciences offers analytical and technology services.

**2. For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product (optional):**

(a). **Reduction during sourcing/ production/ distribution achieved since the previous year throughout the value chain?**

Suven is into the niche area of NCE development. Under NCE

development, materials (primarily chemicals and additives) required vary widely. Since these are research projects, there is no defined standard for material procurement or quantum of usage. Hence, measuring reduction during sourcing does not seem to be not an appropriate efficiency benchmark for the Company.

(b). **Reduction during usage by consumers (energy, water) has been achieved since the previous year?**

Suven's innovation-focused business leverages its knowledge and skill to develops New Chemical Entities (NCEs) that address CNS-related ailments. Hence there is no specific standard for consumption of utilities namely energy, water etc. As a result, measuring the quantum of reduction in utilities is not relevant for the Company. Despite this reality, the Company, at its labs, adheres to systems and processes that are approved by globally respected and reputed regulatory authorities - this ensures that the consumption of utilities is optimised. Further, disciplined operations and real time monitoring of every process in its labs helps in reducing wastages.

**3. Does the Company have procedures in place for sustainable sourcing (including transportation)?**

Yes. At Suven, we have defined processes for addressing all sustainable sourcing of all key elements required in our business operations.

(a). **If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about 50 words or so.**

We continuously strive to maintain the best practices for sustainable sourcing (number of partners: around 60). To ensure the seamless availability of all critical resources, we continue to identify alternate sources

which ensures business continuity.

**4. Has the Company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work?**

Yes.

(a) **If yes, what steps have been taken to improve their capacity and capability of local and small vendors?**

The Company strives to improve the business of its vendors. It provides technical inputs to small vendors for improving product quality and operational efficiency. The company periodically informs small vendors of its innovation plans to enable them to align their products/intermediates/ reagents with the Company's innovation aspirations.

**5. Does the Company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about 50 words or so.**

Suven is primarily into research and development of New Chemical Entities. As such, its operating infrastructure comprises R&D labs. As such its operations do not pose a significant burden on the environment. But, as an Earth-respecting corporate, the Company remains vigilant on its resource utilisation. Moreover, stringent adherence to globally-accepted lab processes ensures that its operations remain safe and waste-generation is minimised.

As a quality-focused organisation, the Company does not reprocess products which have failed the quality test. However, incidents of quality failure of products are rare and insignificant.



### Principle 3

1.	Please indicate the Total number of employees.	We have 130 employees as on 31 March 2021.
2.	Please indicate the Total number of employees hired on temporary/ contractual/ casual basis.	We have 12 casual employees on contract as on 31 March 2021.
3.	Please indicate the Number of permanent women employees.	We have 29 women employees as on 31 March 2021.
4.	Please indicate the Number of permanent employees with disabilities	NIL
5.	Do you have an employee association that is recognised by management	The Company does not have an employee association
6.	What percentage of your permanent employees is members of this recognised employee association?	NA
7.	Please indicate the Number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last financial year and pending, as on the end of the financial year.	NIL

No.	Category	No of complaints filed during the financial year	No of complaints pending as on end of the financial year
1	Child labour/forced labour/involuntary labour	NIL	NIL
2	Sexual harassment	NIL	NIL
3	Discriminatory employment	NIL	NIL

8	What percentage of your under mentioned employees were given safety & skill up- gradation training in the last year?	Being a research-based organisation, Suven continuously focuses on enhancing the intellectual capital of its people by providing training on various technical aspects and on behavioral skills for all round development of its team. In addition, the Company also works on enhancing the awareness of its team on people-critical issues such safety and health.
	(a) Permanent Employees (b) Permanent Women Employees	Nil
	(c) Casual/Temporary/Contractual Employees	Nil
	(d) Employees with Disabilities	Nil

### Principle 4


1	Has the Company mapped its internal and external stakeholders? Yes/No.	Yes, we have mapped our internal and external stakeholders.
2.	Out of the above, has the Company identified the disadvantaged, vulnerable & marginalised stakeholders	Yes, we have identified disadvantaged, vulnerable & marginalised stakeholders.
3	Are there any special initiatives taken by the Company to engage with the disadvantaged, vulnerable and marginalised stakeholders? If so, provide details thereof, in about 50 words or so.	No, during the year the Company did not have any opportunity of dealing with disadvantaged, vulnerable and marginalised stakeholders.

### Principle 5

1.	Does the policy of the Company on human rights cover only the Company or extend to the Group/Joint Ventures/ Suppliers/ Contractors/ NGOs/Others?	At present, our policy is extended to the group, our suppliers, contractors and NGOs.
2.	How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management?	We did not receive any complaints in the last financial year.

### Principle 6

1	Does the policy related to Principle 6 cover only the Company or extends to the Group/ Joint Ventures/ Suppliers/ Contractors/ NGOs/ others.	The policy at present covers the Company, its subsidiary and branches.
2	Does the Company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc.? Y/N. If yes, please give hyperlink for webpage etc.	The Company firmly believes that every organisation must endeavour to reduce its load on the Earth to make the world a better place. In keeping with this philosophy, the Company continues to invest in energy-efficient equipment and alter processes to optimise consumption of utilities (air, water and energy) and minimise noise pollution – thereby minimising its carbon footprint.
3	(c) Casual/Temporary/Contractual Employees	Yes.
4	Does the Company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if yes, whether any environmental compliance report is filed?	At present, the Company does not have any project related to Clean Development Mechanism.
5	Has the Company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc. Y/N. If yes, please give hyperlink for web page etc.	No
6	Are the Emissions/ Waste generated by the Company within the permissible limits given by CPCB/ SPCB for the financial year being reported?	Yes
7	Number of show cause/ legal notices received from CPCB/ SPCB which are pending (i.e. not resolved to satisfaction) as on end of Financial Year.	None.



### Principle 7

1. Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with:
  - a. (a) Pharmaceutical Export Promotion Council
  - b. (b) Bulk Drugs Manufacturers Association
  - c. (c) Telangana Government Pharmaceutical Task Force
2. Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas (drop box: Governance and Administration, Economic Reforms, Inclusive Development Policies, Energy security, Water, Food Security, Sustainable Business Principles, Others)
 

Yes. The Company's Chairman represented Pharmaceutical companies to the Government of India and central policy making bodies in suggesting reforms and development policies for innovative research programs and providing encouragement and incentives for innovation and improvement.

### Principle 8

1. Does the Company have specified programmes/ initiatives/ projects in pursuit of the policy related to Principle 8? If yes details thereof.
 

There is no CSR obligation on Suven Life Sciences (post-demerger), hence there were no community development projects undertaken by the Company.
2. Are the programmes/projects undertaken through in-house team/own foundation/ external NGO/ government structures/ any other organisation?
 

N.A.
3. Have you done any impact assessment of your initiative?
 

N.A.
4. What is your company's direct contribution to community development projects- Amount in INR and the details of the projects undertaken?
 

There is no CSR obligation on Suven Life Sciences (post-demerger), hence no money was spent on community development projects.

5. Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so.
 

Since there were no community development initiatives funded or undertaken by the Company, this does not apply to the Company.

### Principle 9

1. What percentage of customer complaints/ consumer cases are pending as on the end of financial year?
 

Nil
2. Does the Company display product information on the product label, over and above what is mandated as per local laws? Yes/No/N.A. / Remarks (additional information)
 

Yes.
3. Is there any case filed by any stakeholder against the Company regarding unfair trade practices, irresponsible advertising and/or anticompetitive behaviour during the last five years and pending as on end of financial year? If so, provide details thereof, in about 50 words or so.
 

No. Investor complaints as and when received are addressed immediately and the status of such complaints is provided as part of the Annual Report.
4. Did your company carry out any consumer survey/ consumer satisfaction trends?
 

No. As the Company's products are not intended for direct consumption by consumers.



**SUVEN  
LIFE SCIENCES LIMITED**

CIN: L24110TG1989PLC009713  
SDE SERENE CHAMBERS  
ROAD NO. 5, AVENUE 7  
BANJARA HILLS  
HYDERABAD - 500 034  
TELANGANA